Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SGN-TGT |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-TGT | SGN TGT|SEA-TGT|SGNTGT | TIGIT Antibody 13 | SGN-TGT is a nonfucosylated monoclonal antibody targeting the immune checkpoint inhibitor TIGIT that binds to its target on tumor-infiltrating lymphocytes, inhibiting the interaction of TIGIT with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of the anti-tumor immune response (NCI Drug Dictionary; Annals of Oncology. 2020 Sep 1;31:S729-30). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Recruiting | USA | ITA | FRA | ESP | CAN | 1 |